as on October 30, 2025 at 1:29 am IST
Day's Low
Day's High
1.50%
Downside
3.59%
Upside
52 Week's Low
52 Week's High
16.67%
Downside
97.80%
Upside
Check Summit Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$14.3B
EPS (TTM)
-0.8154
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-15.59
Industry PE ratio
8.355964912280701
PEG Ratio
0EBITDA
-935.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-292.49%
Track how Summit Therapeutics Inc P/E has moved over time to understand its valuation trends.
Summit Therapeutics Inc in the last 5 years
Lowest (-72.24x)
March 31, 2025
Today (-15.59x)
October 30, 2025
Industry (8.36x)
October 30, 2025
Highest (-0.61x)
April 30, 2023
Today’s Price to Earnings Ratio: -15.59x
Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $14.3B | 470.64% | -15.59 | 0.00% | |
| BUY | $62.4B | 291.63% | -505.15 | -12.96% | |
| NA | $36.4B | NA | NA | -3.89% | |
| BUY | $108.3B | 100.24% | 30.02 | 31.86% | |
| BUY | $69.4B | 20.12% | 15.7 | 32.13% |
The Summit Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Summit Therapeutics Inc investment value today
Current value as on today
₹1,05,115
Returns
₹5,115
(+5.11%)
Returns from Summit Therapeutics Inc Stock
₹54 (+0.05%)
Dollar Returns*
₹5,061 (+5.06%)
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc. Average target price of $31.65
Get share price movements and forecasts by analysts on Summit Therapeutics Inc.
What analysts predicted
41.04%UPSIDE
Target Price
$31.65
Current Price
$18.66
Analyzed by
7 Analysts
Target
$31.65
Summit Therapeutics Inc target price $31.65, a slight upside of 41.04% compared to current price of $18.66. According to 7 analysts rating.
Investment in Summit Therapeutics Inc Shares on INDmoney has dropped by -48.16% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Summit Therapeutics Inc Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 20 October
Mon, 05:33 PM
-Summit Therapeutics reports Q3 2025 financials, highlighting significant net loss and increased operating expenses amid ongoing clinical trials.
Mon, 07:35 PM
-Summit announces plans for a Biologics License Application submission and new Phase 3 studies for ivonescimab.
Mon, 10:28 PM
-Summit reports higher R&D expenses in Q3 2025, exceeding analyst estimates, amid competitive trial results.
Today's Timeline - 20 October
Mon, 11:22 PM
-JMP Securities reiterates Market Outperform recommendation for Summit, with a price target increase reflecting positive outlook.
Tue, 00:22 AM
-Summit initiates Phase III study for colorectal cancer, reports positive trial results, and outlines future clinical expansions.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 3 years, SMMT stock has moved up by 1596.4%
Best in 3 Years
![]()
In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.1% return, outperforming this stock by 71.0%
Revenue Fall
![]()
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
Profit Down
![]()
Netprofit is down for the last 4 quarters, -56.25M → -231.79M (in $), with an average decrease of 93.3% per quarter
| Organisation | Summit Therapeutics Inc |
| Headquarters | 601 Brickell Key Drive, Miami, FL, United States, 33131 |
| Industry | Health Technology |
| CEO | Mr. Robert W. Duggan |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Nathan LiaBraaten | Senior Director of Investor Relations |
Mr. Dave Gancarz | Chief Business & Strategy Officer |
Dr. Fong Clow | Chief Biometrics Officer |
Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
Mr. Bhaskar Anand | Chief Accounting Officer |
Summit Therapeutics Inc share price today is $18.66 as on at the close of the market. Summit Therapeutics Inc share today touched a day high of $19.33 and a low of $18.38.
Summit Therapeutics Inc share touched a 52 week high of $36.91 on and a 52 week low of $15.55 on . Summit Therapeutics Inc stock price today i.e. is closed at $18.66,which is 49.44% down from its 52 week high and 20.00% up from its 52 week low.
Summit Therapeutics Inc market capitalisation is $0.01T as on .
Indian investors can start investing in Summit Therapeutics Inc (SMMT) shares with as little as ₹88.178 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.78 in Summit Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Summit Therapeutics Inc share’s latest price of $18.66 as on October 30, 2025 at 1:29 am IST, you will get 0.5359 shares of Summit Therapeutics Inc. Learn more about
fractional shares .
Summit Therapeutics Inc stock has given 470.64% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?